ProMIS Neurosciences, Inc. (PMN)
NASDAQ: PMN · Real-Time Price · USD
16.09
-0.07 (-0.43%)
At close: Feb 20, 2026, 4:00 PM EST
15.65
-0.44 (-2.72%)
After-hours: Feb 20, 2026, 7:44 PM EST
ProMIS Neurosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
8
Market Cap
144.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 1.23K | 301.00 | 32.47% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 148.20M |
| Sangamo Therapeutics | 32.88M |
| ProQR Therapeutics | 18.86M |
| Innate Pharma | 14.84M |
| Whitehawk Therapeutics | 14.38M |
| Connect Biopharma Holdings | 762.00K |
| Adagene | 103.20K |
PMN News
- 17 days ago - ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - GlobeNewsWire
- 22 days ago - ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - GlobeNewsWire
- 2 months ago - ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces Reverse Stock Split - GlobeNewsWire
- 3 months ago - ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights - GlobeNewsWire